Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Use of Antiemetic Agents in Acute Gastroenteritis 3. 2008 Exclusive Survey—Earnings: Good news for primary care income 4. Medicare pay-for-reporting effort draws fire from frustrated doctors 5. Debunking Myths in the US Healthcare System
Your Article Summary
See Latest ArticlesA Randomized, Controlled, Dose-ranging Study Investigating Single Doses of GW406381, Naproxen Sodium, or Placebo in Patients With Acute Pain After Third Molar Tooth Extraction
The Clinical Journal of Pain, 08/21/09
Varner J et al. – Pain relief intensity differences from placebo were statistically significant beginning at 1.5 hours postdosing for GW406381 70 and 50 mg and at 2–hour postdosing for GW406381 25 and 10 mg. The median time to onset of analgesia was 71 minutes for GW406381 50 mg, 72 minutes for GW406381 70 mg, and 36 minutes for naproxen. The median duration of analgesia was 5.9 hours for GW406381 50 mg, 7.9 hours for GW406391 70 mg, and 11.3 hours for naproxen. All treatments were well tolerated. GW406381 50 and 70 mg demonstrated clinically meaningful analgesia in this acute pain setting, although the onset of analgesia was greater than 1 hour.
Today in Pain Management...keeping you current
Receive free subspecialty "5-minute updates" via email
Escitalopram and Venlafaxine for the Prophylaxis of Migraine Headache Without Mood Disorders
Clinical Neuropharmacology, 10/02/09
Acute back pain: benefits and risks of current treatments
Current Medical Research and Opinion, 11/19/09
Migraine Chronification - Concept and Risk Factors
Discovery Medicine, 10/27/09
Article Search
Sponsor